xigduo® xr 10 mg/500 mg film-coated tablet
astrazeneca uk limited; importer: astrazeneca pharmaceuticals (phils.), inc. - dapagliflozin (as propanediol monohydrate) , metformin hydrochloride - film-coated tablet - 10 mg/500 mg
forxiga 5 mg film-coated tablet
astrazeneca pharmaceuticals (phils.), inc.; distributor: astrazeneca pharmaceuticals (phils.), inc. - dapagliflozin (as propanediol monohydrate) - film-coated tablet - 5 mg
forxiga 10 mg film-coated tablet
astrazeneca pharmaceuticals (phils.), inc.; distributor: astrazeneca pharmaceuticals (phils.), inc. - dapagliflozin (as propanediol monohydrate) - film-coated tablet - 10 mg
forxiga® 10 mg film-coated tablet
n/a; importer: astrazeneca pharmaceuticals (phils.), inc.; distributor: astrazeneca pharmaceuticals (phils.), inc. - dapagliflozin (as propanediol monohydrate) - film-coated tablet - 10 mg
forxiga 5 mg film-coated tablet
astrazeneca uk ltd.; importer: astrazeneca pharmaceuticals (phils.), inc.; distributor: astrazeneca pharmaceuticals (phils.), inc. - dapagliflozin (as propanediol monohydrate) - film-coated tablet - 5 mg
xigduo 5 mg/850 mg film-coated tablets
astrazeneca ab - metformin hydrochloride, dapagliflozin propanediol monohydrate - film-coated tablet (tablet) - 5 mg/850 mg - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose-lowering drugs - indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control - in patients inadequately controlled on their maximally tolerated dose of metformin alone - in combination with other glucose-lowering medicinal products, including insulin, in patients inadequately controlled with metformin and these medicinal products - in patients already being treated with the combination of dapagliflozin and metformin as separate tablets
xigduo 5 mg/1,000 mg film-coated tablets
astrazeneca ab - metformin hydrochloride, dapagliflozin propanediol monohydrate - film-coated tablet (tablet) - 5 mg/1,000 mg - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose-lowering drugs - indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control - in patients inadequately controlled on their maximally tolerated dose of metformin alone - in combination with other glucose-lowering medicinal products, including insulin, in patients inadequately controlled with metformin and these medicinal products - in patients already being treated with the combination of dapagliflozin and metformin as separate tablets
qtern
astrazeneca (israel) ltd - dapagliflozin as propanediol; saxagliptin as hydrochloride monohydrate - film coated tablets - dapagliflozin as propanediol 10 mg; saxagliptin as hydrochloride monohydrate 5 mg - saxagliptin and dapagliflozin - qtern, fixed dose combination of saxagliptin and dapagliflozin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:- to improve glycaemic control when metformin and/or sulphonylurea (su) and one of the monocomponents of qtern do not provide adequate glycaemic control,- when already being treated with the free combination of dapagliflozin and saxagliptin.
qtern
astrazeneca (israel) ltd - dapagliflozin as propanediol; saxagliptin as hydrochloride monohydrate - film coated tablets - dapagliflozin as propanediol 10 mg; saxagliptin as hydrochloride monohydrate 5 mg - saxagliptin and dapagliflozin - qtern, fixed dose combination of saxagliptin and dapagliflozin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:- to improve glycaemic control when metformin and/or sulphonylurea (su) and one of the monocomponents of qtern do not provide adequate glycaemic control,- when already being treated with the free combination of dapagliflozin and saxagliptin.
qtern
astrazeneca (israel) ltd - dapagliflozin as propanediol; saxagliptin as hydrochloride monohydrate - film coated tablets - dapagliflozin as propanediol 10 mg; saxagliptin as hydrochloride monohydrate 5 mg - saxagliptin and dapagliflozin - qtern, fixed dose combination of saxagliptin and dapagliflozin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:- to improve glycaemic control when metformin and/or sulphonylurea (su) and one of the monocomponents of qtern do not provide adequate glycaemic control,- when already being treated with the free combination of dapagliflozin and saxagliptin.